COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes.

Rebecca H HabermanRochelle CastilloAlan ChenDi YanDeborah RamirezVaish SekarRobert LesserGary SolomonAndrea L NeimannRebecca B BlankPeter M IzmirlyDan E WebsterAlexis OgdieAndrea B TroxelSamrachana AdhikariJose U Schernull null

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2020)

Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
respiratory syndrome coronavirus
risk factors
oxidative stress
adipose tissue
cell therapy
disease activity